FEV1 is a stronger mortality predictor than FVC in patients with moderate COPD and with an increased risk for cardiovascular disease
暂无分享,去创建一个
F. Martinez | P. Calverley | R. Brook | B. Celli | J. Vestbo | J. Yates | D. Newby | C. Crim | Julie A. Anderson | P. Lange | A. Bikov | N. Cowans | Ian J. Dixon | J. Anderson
[1] V. Kim,et al. Serum biomarkers and outcomes in patients with moderate COPD: a substudy of the randomised SUMMIT trial , 2019, BMJ Open Respiratory Research.
[2] S. Yusuf,et al. Mortality and cardiovascular and respiratory morbidity in individuals with impaired FEV1 (PURE): an international, community-based cohort study. , 2019, The Lancet. Global health.
[3] Renata Ferrari,et al. Predictors of mortality in patients with COPD after 9 years , 2018, International journal of chronic obstructive pulmonary disease.
[4] K. Rabe,et al. Cardiovascular disease and COPD: dangerous liaisons? , 2018, European Respiratory Review.
[5] F. Martinez,et al. Exacerbations of Chronic Obstructive Pulmonary Disease and Cardiac Events: A Cohort Analysis , 2018 .
[6] A. Anzueto,et al. Determinants of exacerbation risk in patients with COPD in the TIOSPIR study , 2017, International journal of chronic obstructive pulmonary disease.
[7] A. Briggs,et al. Prediction models for exacerbations in different COPD patient populations: comparing results of five large data sources , 2017, International journal of chronic obstructive pulmonary disease.
[8] J. Wedzicha,et al. Global Strategy for the Diagnosis, Management, and Prevention of Chronic Obstructive Lung Disease 2017 Report. GOLD Executive Summary. , 2017, American journal of respiratory and critical care medicine.
[9] J. Wedzicha,et al. Global Strategy for the Diagnosis, Management, and Prevention of Chronic Obstructive Lung Disease 2017 Report: GOLD Executive Summary , 2017, European Respiratory Journal.
[10] F. Martinez,et al. Fluticasone furoate and vilanterol and survival in chronic obstructive pulmonary disease with heightened cardiovascular risk (SUMMIT): a double-blind randomised controlled trial , 2016, The Lancet.
[11] Alice M Turner,et al. Mortality prediction in chronic obstructive pulmonary disease comparing the GOLD 2007 and 2011 staging systems: a pooled analysis of individual patient data. , 2015, The Lancet. Respiratory medicine.
[12] Alvar Agusti,et al. Hospitalized exacerbations of COPD: risk factors and outcomes in the ECLIPSE cohort. , 2015, Chest.
[13] Edwin K. Silverman,et al. Chronic obstructive pulmonary disease , 2012, Nature Reviews Disease Primers.
[14] N. Metzdorf,et al. Does the 2013 GOLD classification improve the ability to predict lung function decline, exacerbations and mortality: a post-hoc analysis of the 4-year UPLIFT trial , 2014, BMC Pulmonary Medicine.
[15] L. Edwards,et al. Coronary artery calcification is increased in patients with COPD and associated with increased morbidity and mortality , 2014, Thorax.
[16] D. Mannino,et al. Chronic obstructive pulmonary disease mortality and prevalence: the associations with smoking and poverty—a BOLD analysis , 2013, Thorax.
[17] Bruce G. Link,et al. The impact of obesity on US mortality levels: the importance of age and cohort factors in population estimates. , 2013, American journal of public health.
[18] F. Martinez,et al. The Study to Understand Mortality and Morbidity in COPD (SUMMIT) study protocol , 2012, European Respiratory Journal.
[19] Courtney Crim,et al. Persistent Systemic Inflammation is Associated with Poor Clinical Outcomes in COPD: A Novel Phenotype , 2012, PloS one.
[20] P. Burney,et al. Forced vital capacity, airway obstruction and survival in a general population sample from the USA , 2010, Thorax.
[21] J. Wedzicha,et al. Susceptibility to exacerbation in chronic obstructive pulmonary disease. , 2010, The New England journal of medicine.
[22] R. Hubbard,et al. Increased risk of myocardial infarction and stroke following exacerbation of COPD. , 2010, Chest.
[23] J. Hankinson,et al. Standardisation of spirometry , 2005, European Respiratory Journal.
[24] D. Sin,et al. The relationship between reduced lung function and cardiovascular mortality: a population-based study and a systematic review of the literature. , 2005, Chest.
[25] Ciro Casanova,et al. The body-mass index, airflow obstruction, dyspnea, and exercise capacity index in chronic obstructive pulmonary disease. , 2004, The New England journal of medicine.
[26] Don D. Sin,et al. Why Are Patients With Chronic Obstructive Pulmonary Disease at Increased Risk of Cardiovascular Diseases?: The Potential Role of Systemic Inflammation in Chronic Obstructive Pulmonary Disease , 2003 .
[27] M. Segal,et al. Relation of FEV1 and peripheral blood leukocyte count to total mortality. The Normative Aging Study. , 1995, American journal of epidemiology.
[28] E. Metter,et al. Rapid decline in FEV1. A new risk factor for coronary heart disease mortality. , 1995, American journal of respiratory and critical care medicine.
[29] D. Dockery,et al. Chronic obstructive pulmonary disease mortality in six U.S. cities. , 1989, The American review of respiratory disease.
[30] A. Siegelaub,et al. Lung function and risk of myocardial infarction and sudden cardiac death. , 1976, The New England journal of medicine.